World Journal of
Pharmaceutical and Life Sciences

DEVELOPMENT OF A STABLE FORMULATION OF DOXORUBICIN LIPOSOMAL INJECTION: BIOLOGICAL PERSPECTIVE

Dr. Sushil Rana*, Dr. Deep Narayan Sharma, Sahil Chandel and Abhishek Jain

ABSTRACT

The development of liposomal drug formulations has revolutionized oncological therapeutics, offering targeted and controlled delivery systems that enhance efficacy while reducing systemic toxicity to the patients. Present research explores the innovative methodologies of Liposomal Doxorubicin Hydrochloride employed by Biozenta Lifesciences Pvt. Ltd., a leading pharmaceutical enterprise renowned for its high-quality oncology formulations. One of the company’s landmark innovations is the development of liposomal Doxorubicin, a chemotherapy drug encapsulated in lipid bilayers to improve pharmacokinetics, bioavailability, and patient outcomes. This approach utilizes cutting-edge nanotechnology to encapsulate Doxorubicin. The liposomal design minimizes cardio toxicity and myelosuppression, common adverse effects of traditional doxorubicin therapy, while improving therapeutic efficacy. Innovative methods were used to stabilize the liposome formation, such as high-resolution transmission electron microscopy and HPLC analysis to confirm the particle lamellarity, size uniformity, and drug entrapment efficiency, achieving an impressive 98% encapsulation rate with nanoscale size (314.16 nm) and stable zeta potential (-0.5 mV) of the liposomes, ensuring effective tumor penetration and prolonged circulation time, enhancing drug efficacy and minimizing systemic toxicity.

[Full Text Article]   [Download Certificate]